176 related articles for article (PubMed ID: 22437624)
1. Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation.
Carpenter WR; Meyer AM; Wu Y; Qaqish B; Sanoff HK; Goldberg RM; Weiner BJ
Med Care; 2012 Aug; 50(8):737-48. PubMed ID: 22437624
[TBL] [Abstract][Full Text] [Related]
2. Provider-based research networks may improve early access to innovative colon cancer treatment for African Americans treated in the community.
Penn DC; Chang Y; Meyer AM; DeFilippo Mack C; Sanoff HK; Stitzenberg KB; Carpenter WR
Cancer; 2015 Jan; 121(1):93-101. PubMed ID: 25209056
[TBL] [Abstract][Full Text] [Related]
3. Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer.
Tan HJ; Meyer AM; Kuo TM; Smith AB; Wheeler SB; Carpenter WR; Nielsen ME
Cancer; 2015 Mar; 121(6):836-43. PubMed ID: 25410684
[TBL] [Abstract][Full Text] [Related]
4. Differential receipt of sentinel lymph node biopsy within practice-based research networks.
Meyer AM; Reeder-Hayes KE; Liu H; Wheeler SB; Penn D; Weiner BJ; Carpenter WR
Med Care; 2013 Sep; 51(9):812-8. PubMed ID: 23942221
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
[TBL] [Abstract][Full Text] [Related]
6. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.
Mack CD; Carpenter W; Meyer AM; Sanoff H; Stürmer T
Cancer; 2012 Jun; 118(11):2925-34. PubMed ID: 22072441
[TBL] [Abstract][Full Text] [Related]
7. The role of organizational affiliations and research networks in the diffusion of breast cancer treatment innovation.
Carpenter WR; Reeder-Hayes K; Bainbridge J; Meyer AM; Amos KD; Weiner BJ; Godley PA
Med Care; 2011 Feb; 49(2):172-9. PubMed ID: 21206296
[TBL] [Abstract][Full Text] [Related]
8. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
Ejaz A; Casadaban L; Maker AV
J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Oxaliplatin Versus 5-flourouricil in Older Adults: An Instrumental Variable Analysis.
Mack CD; Brookhart MA; Glynn RJ; Meyer AM; Carpenter WR; Sandler RS; Stürmer T
Epidemiology; 2015 Sep; 26(5):690-9. PubMed ID: 26196683
[TBL] [Abstract][Full Text] [Related]
10. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
11. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
Panchal JM; Lairson DR; Chan W; Du XL
Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
[TBL] [Abstract][Full Text] [Related]
12. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA
JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557
[TBL] [Abstract][Full Text] [Related]
13. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.
Sanoff HK; Carpenter WR; Freburger J; Li L; Chen K; Zullig LL; Goldberg RM; Schymura MJ; Schrag D
Cancer; 2012 Sep; 118(17):4309-20. PubMed ID: 22294436
[TBL] [Abstract][Full Text] [Related]
14. Geographic Variation in Oxaliplatin Chemotherapy and Survival in Patients With Colon Cancer.
Panchal JM; Lairson DR; Chan W; Du XL
Am J Ther; 2016; 23(3):e720-9. PubMed ID: 24368611
[TBL] [Abstract][Full Text] [Related]
15. Implementing community-based provider participation in research: an empirical study.
Teal R; Bergmire DM; Johnston M; Weiner BJ
Implement Sci; 2012 May; 7():41. PubMed ID: 22568935
[TBL] [Abstract][Full Text] [Related]
16. Provider-based research networks demonstrate greater hospice use for minority patients with lung cancer.
Penn DC; Stitzenberg KB; Cobran EK; Godley PA
J Oncol Pract; 2014 Jul; 10(4):e182-90. PubMed ID: 24781367
[TBL] [Abstract][Full Text] [Related]
17. Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy.
Mack CD; Glynn RJ; Brookhart MA; Carpenter WR; Meyer AM; Sandler RS; Stürmer T
Pharmacoepidemiol Drug Saf; 2013 Aug; 22(8):810-8. PubMed ID: 23296544
[TBL] [Abstract][Full Text] [Related]
18. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
[TBL] [Abstract][Full Text] [Related]
19. Practice setting and physician influences on judgments of colon cancer treatment by community physicians.
McFall SL; Warnecke RB; Kaluzny AD; Ford L
Health Serv Res; 1996 Apr; 31(1):5-19. PubMed ID: 8617610
[TBL] [Abstract][Full Text] [Related]
20. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.
Sanoff HK; Carpenter WR; Stürmer T; Goldberg RM; Martin CF; Fine JP; McCleary NJ; Meyerhardt JA; Niland J; Kahn KL; Schymura MJ; Schrag D
J Clin Oncol; 2012 Jul; 30(21):2624-34. PubMed ID: 22665536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
